Plasmon-waveguide resonance studies of ligand binding to the human beta 2-adrenergic receptor.

Plasmon-waveguide resonance (PWR) spectroscopy is an optical technique that can be used to probe the molecular interactions occurring within anisotropic proteolipid membranes in real time without requiring molecular labeling. This method directly monitors mass density, conformation, and molecular orientation changes occurring in such systems and allows determination of protein-ligand binding constants and binding kinetics. In the present study, PWR has been used to monitor the incorporation of the human beta(2)-adrenergic receptor into a solid-supported egg phosphatidylcholine lipid bilayer and to follow the binding of full agonists (isoproterenol, epinephrine), a partial agonist (dobutamine), an antagonist (alprenolol), and an inverse agonist (ICI-118,551) to the receptor. The combination of differences in binding kinetics and the PWR spectral changes point to the occurrence of multiple conformations that are characteristic of the type of ligand, reflecting differences in the receptor structural states produced by the binding process. These results provide new evidence for the conformational heterogeneity of the liganded states formed by the beta(2)-adrenergic receptor.

[1]  Terry Kenakin,et al.  Ligand-selective receptor conformations revisited: the promise and the problem. , 2003, Trends in pharmacological sciences.

[2]  Z. Salamon,et al.  Binding of agonists, antagonists and inverse agonists to the human delta-opioid receptor produces distinctly different conformational states distinguishable by plasmon-waveguide resonance spectroscopy. , 2002, The journal of peptide research : official journal of the American Peptide Society.

[3]  Terry Kenakin,et al.  Efficacy at g-protein-coupled receptors , 2002, Nature Reviews Drug Discovery.

[4]  S. Edelstein,et al.  The Neurokinin A Receptor Activates Calcium and cAMP Responses through Distinct Conformational States* , 2001, The Journal of Biological Chemistry.

[5]  P Ghanouni,et al.  Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor* , 2001, The Journal of Biological Chemistry.

[6]  R. Zare,et al.  Single-molecule spectroscopy of the β2 adrenergic receptor: Observation of conformational substates in a membrane protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P Ghanouni,et al.  Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Z. Salamon,et al.  Plasmon resonance studies of agonist/antagonist binding to the human delta-opioid receptor: new structural insights into receptor-ligand interactions. , 2000, Biophysical journal.

[9]  S. Havelund,et al.  Ligand-induced conformational change in the minimized insulin receptor. , 2000, Journal of molecular biology.

[10]  S. Hill,et al.  Non‐competitive antagonism of β2‐agonist‐mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active β2‐adrenoceptors , 2000, British journal of pharmacology.

[11]  Z. Salamon,et al.  Interaction of phosphatidylserine synthase from E. coli with lipid bilayers: coupled plasmon-waveguide resonance spectroscopy studies. , 2000, Biophysical journal.

[12]  U. Gether.  Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.

[13]  Z. Salamon,et al.  Plasmon resonance spectroscopy: probing molecular interactions within membranes. , 1999, Trends in biochemical sciences.

[14]  Z. Salamon,et al.  Surface Plasmon Resonance, Applications , 1999 .

[15]  Surface Plasmon Resonance, Theory , 1999 .

[16]  Z. Salamon,et al.  Coupled plasmon-waveguide resonance spectroscopy studies of the cytochrome b6f/plastocyanin system in supported lipid bilayer membranes. , 1998, Biophysical journal.

[17]  B. Kobilka,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[18]  Heidi E. Hamm,et al.  The Many Faces of G Protein Signaling* , 1998, The Journal of Biological Chemistry.

[19]  H. Macleod,et al.  Coupled plasmon-waveguide resonators: a new spectroscopic tool for probing proteolipid film structure and properties. , 1997, Biophysical journal.

[20]  A. Strosberg.  STRUCTURE AND FUNCTION OF THE 3 -ADRENERGIC RECEPTOR , 1997 .

[21]  A. Strosberg,et al.  Structure and function of the beta 3 adrenoreceptor. , 1998, Advances in pharmacology.

[22]  Z. Salamon,et al.  Surface plasmon resonance spectroscopy studies of membrane proteins: transducin binding and activation by rhodopsin monitored in thin membrane films. , 1996, Biophysical journal.

[23]  B. Kobilka,et al.  Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. , 1995, The Journal of biological chemistry.

[24]  B. Kobilka.  Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. , 1995, Analytical biochemistry.

[25]  B. Kobilka,et al.  Adrenergic receptor signal transduction and regulation , 1995, Neuropharmacology.

[26]  Kolakowski Lf.  GCRDB: A G-PROTEIN-COUPLED RECEPTOR DATABASE , 1994 .

[27]  L. F. Kolakowski.  GCRDb: a G-protein-coupled receptor database. , 1994, Receptors & channels.

[28]  S. Green,et al.  A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.

[29]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[30]  P. Silberzan,et al.  Silanation of silica surfaces. A new method of constructing pure or mixed monolayers , 1991 .

[31]  L. White,et al.  Hydrophobicity effects in the condensation of water films on quartz , 1990 .

[32]  B. M. Baron,et al.  p-[125I]iodoclonidine, a novel radiolabeled agonist for studying central alpha 2-adrenergic receptors. , 1990, Molecular pharmacology.

[33]  J. Venter,et al.  Continuous high density expression of human beta 2-adrenergic receptors in a mouse cell line previously lacking beta-receptors. , 1987, The Journal of biological chemistry.

[34]  J. Fitzgerald,et al.  The Pharmacology of a β2‐Selective Adrenoceptor Antagonist (ICI 118,551) , 1983 .